Skip to content

Combined PRF and Fibroblasts in Acne Scar Treatment

Investigating the efficacy of platelet-rich fibrin (PRF) injection in combination with autologous fibroblast compared to autologous fibroblast injection alone in the treatment of atrophic acne scars in patients treated with CO2 fractional laser: a double-blind clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220808055641N6
Enrollment
10
Registered
2025-11-05
Start date
2025-11-05
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne scar. Atrophic disorders of skin

Interventions

Intervention 1: Intervention group: In this study, one randomly selected side of each patient’s face will receive intralesional injection of autologous fibroblasts combined with platelet-rich fibrin (

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Diagnosis of Atrophic Acne Scars Participants must have received fractional CO2 laser therapy before the initiation of the study. A minimum of 10 days should have elapsed since the most recent fractional CO2 laser session.

Exclusion criteria

Exclusion criteria: Individuals younger than 18 or older than 65 years of age. Atrophic acne scars that have formed within the last 6 months. Any therapeutic intervention for atrophic scars within the past month, except fractional CO2 laser treatment. Bleeding or coagulation disorders. Pregnancy

Design outcomes

Primary

MeasureTime frame
Improvement of acne atrophic scar. Timepoint: The beginning of the study and 1 month after the start of the study and 3 months after the start of the study. Method of measurement: sonography;visioface;biometery;cutometery,physician global assessment score;patient global assessment score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Jafarzadeh

Tehran University of Medical Sciences

alirezajafarzadeh8@gmail.com+98 919 890 7445

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026